Diagnostics company Cancer Genetics again decreases proposed deal size

By
A A A

Cancer Genetics, which offers personalized genomic tests to improve the diagnosis and treatment of cancer, lowered the proposed deal size for its upcoming IPO on Monday. The Rutherford, NJ-based company now plans to raise $20 million by offering 1.9 million shares at a price range of $10 to $12. The company had previously filed to offer 5 million shares at a range of $4 to $6. At the midpoint of the revised range, Cancer Genetics will raise -19% fewer proceeds than previously anticipated.

Cancer Genetics originally filed for an IPO in December 2011 before postponing the deal in May 2012 and then again in February 2013. Its first attempted deal aimed to raise $48 million. The company, which was founded in 1999 and booked $4 million in sales for the 2012 fiscal year, plans to list on the NASDAQ under the symbol CGIX. Aegis Capital is the lead bookrunner on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CGIX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com